Mike Romanos wins promotion

Becomes chief executive of Crescendo Biologics

Crescendo Biologics has appointed Mike Romanos as chief executive.

Romanos has been chief scientific officer of the Cambridge, UK-based company since May 2009 and has led its formation and the development of its proprietary antibody fragment technologies.

Since 2009 Crescendo has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. These ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.

You may also like

Research & Development
Crescendo Biologics announces cancer research collaboration

Crescendo Biologics announces cancer research collaboration

Dr Andrew Pierce, VP Translational Biology at Crescendo, said: “The ICR is a world-renowned research institution, and we are very excited to have the opportunity to collaborate with Professor de Bono and his team"
Research & Development
Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company
Research & Development

Crescendo Biologics expands ADC programmes with Innovate UK grant

Award will support development of new therapies to target prostate cancer
Research & Development

Multi million pound seed funding enables Crescendo Biologics to advance fragment antibody technology

<p>Crescendo Biologics has raised £4.5m in a seed funding round
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
Bavarian Nordic secures four-year UK vaccine supply contract

Bavarian Nordic secures four-year UK vaccine supply contract

The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox vaccine, supporting the UK's long-term infectious disease preparedness
Subscribe now